CBIO
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 6.56 · operating margin -1408% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. Weekly bias is flat
VENTE TOTALE: 9 447 titres (~159 775,27 $ US)
- Insiders
- Brumm Joshua T
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$159,775
Avg sell (VWAP, 90d window) $17.07 vs last close $14.24 (-16.6%)
- Last activity
- 2026-09-18
- Liquidity
- Thin $7,620,948/day · 20d vol
- Last synced
-
2026-09-24 21:10:15
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-18 | Brumm Joshua T | Sell | 7,837 | $16.71 | $130,956 | Form 4 |
| 2026-09-18 | McNeill Jonathan | Sell | 3,839 | $16.71 | $64,150 | Form 4 |
| 2026-09-16 | Bispham Barbara Harlin | Sell | 620 | $17.90 | $11,098 | Form 4 |
| 2026-09-16 | Brumm Joshua T | Sell | 1,610 | $17.90 | $28,819 | Form 4 |
| 2026-09-16 | Im Ellie Eunkyung | Sell | 623 | $17.90 | $11,152 | Form 4 |
| 2026-09-16 | Lynch Ryan | Sell | 240 | $17.90 | $4,296 | Form 4 |
| 2026-09-16 | McNeill Jonathan | Sell | 731 | $17.90 | $13,085 | Form 4 |
| 2026-09-16 | Pinkas Jan | Sell | 658 | $17.90 | $11,778 | Form 4 |
| 2026-09-16 | Scalzo Richard William | Sell | 568 | $17.90 | $10,167 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-23
CBIO presents a deeply concerning investment profile combining severe financial distress (persistent losses, -14.2% net margin, 605-day CCC) with a complete absence of positive catalysts.
The first sentence of the analysis written for CBIO on 2026-09-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -1381.0% | 0.0% | -392746.6% | -63203.8% | -5470.7% | |
| Ebitda Margin | -1380.2% | 0.0% | -391213.5% | -62927.6% | -5447.9% | |
| Operating Profit Margin | -1407.5% | 0.0% | -392752.9% | -63204.4% | -5470.7% | |
| Pretax Profit Margin | -1401.2% | 0.0% | -368987.8% | -62251.1% | -5469.0% | |
| Continuous Operations Profit Margin | -1419.6% | 0.0% | -368987.8% | -62251.1% | -5469.0% | |
| Net Profit Margin | -1419.6% | 0.0% | -368994.2% | -62251.7% | -5469.0% | |
| Bottom Line Profit Margin | -1419.6% | 0.0% | -368994.2% | -62251.7% | -5469.0% | |
| Current Ratio | 6.561 | 3.620 | 6.407 | 5.711 | 7.678 | |
| Quick Ratio | 6.561 | 3.620 | 6.407 | 5.711 | 7.678 | |
| Solvency Ratio | -4.127 | -0.949 | -5.324 | -5.234 | -4.957 | |
| Cash Ratio | 5.910 | 3.616 | 6.114 | 5.390 | 7.633 | |
| Price To Earnings Ratio | -0.802 | -0.394 | -4.052 | -3.409 | -1.168 | |
| Price To Earnings Growth Ratio | 0.010 | -0.046 | 0.118 | 0.122 | -0.112 | |
| Forward Price To Earnings Growth Ratio | 0.010 | -0.046 | 0.118 | 0.122 | -0.112 | |
| Price To Earnings Diluted Ratio | -0.802 | -0.394 | -4.052 | -3.409 | -1.168 | |
| Price To Earnings Diluted Growth Ratio | 0.010 | -0.046 | 0.118 | 0.122 | -0.112 | |
| Price To Book Ratio | 0.608 | -1.235 | 3.891 | 3.708 | 0.908 | |
| Price To Sales Ratio | 11.389 | 0.000 | 14,948.806 | 2,122.256 | 63.886 | |
| Price To Free Cash Flow Ratio | -0.855 | -0.614 | -4.283 | -3.420 | -1.288 | |
| Price To Operating Cash Flow Ratio | -1.727 | -0.615 | -4.286 | -3.426 | -1.289 | |
| Debt To Assets Ratio | 0.007 | 1.052 | 0.018 | 0.018 | 0.020 | |
| Debt To Equity Ratio | 0.008 | -2.421 | 0.021 | 0.021 | 0.024 | |
| Debt To Capital Ratio | 0.008 | 1.703 | 0.021 | 0.021 | 0.023 | |
| Long Term Debt To Capital Ratio | 0.000 | 1.703 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.184 | -2.301 | 1.180 | 1.207 | 1.156 | |
| Working Capital Turnover Ratio | 0.096 | 0.000 | 0.000 | 0.001 | 0.011 | |
| Operating Cash Flow Ratio | -1.983 | -3.235 | -5.103 | -5.231 | -4.862 | |
| Operating Cash Flow Sales Ratio | -6.596 | 0.000 | -3,487.990 | -619.433 | -49.570 | |
| Free Cash Flow Operating Cash Flow Ratio | 2.019 | 1.000 | 1.001 | 1.002 | 1.000 | |
| Debt Service Coverage Ratio | -69.416 | -51.847 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | -69.854 | -58.565 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -43.511 | -0.830 | -43.147 | -50.577 | -29.942 | |
| Capital Expenditure Coverage Ratio | -0.981 | -3,118.540 | -1,630.359 | -551.811 | -3,847.255 | |
| Dividend Paid And Capex Coverage Ratio | -0.981 | -3,118.540 | -2.291 | -0.618 | -3,847.255 | |
| Dividend Payout Ratio | 0.000 | 0.000 | -0.412 | -1.609 | 0.000 | |
| Enterprise Value Multiple | 0.588 | -0.494 | -2.774 | -2.378 | 0.225 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲100.0% | ▲20.0% |
| Ebit Margin | -1381.0% | ▼-1381.0% | ▲91179.4% |
| Ebitda Margin | -1380.2% | ▼-1380.2% | ▲90813.6% |
| Operating Profit Margin | -1407.5% | ▼-1407.5% | ▲91159.6% |
| Pretax Profit Margin | -1401.2% | ▼-1401.2% | ▲86220.7% |
| Continuous Operations Profit Margin | -1419.6% | ▼-1419.6% | ▲86205.9% |
| Net Profit Margin | -1419.6% | ▼-1419.6% | ▲86207.3% |
| Bottom Line Profit Margin | -1419.6% | ▼-1419.6% | ▲86207.3% |
| Current Ratio | 6.561 | ▲2.941 | ▲0.565 |
| Quick Ratio | 6.561 | ▲2.941 | ▲0.565 |
| Solvency Ratio | -4.127 | ▼-3.178 | ▼-0.009 |
| Cash Ratio | 5.910 | ▲2.294 | ▲0.177 |
| Price To Earnings Ratio | -0.802 | ▼-0.409 | ▲1.163 |
| Price To Earnings Growth Ratio | 0.011 | ▲0.057 | ▼-0.008 |
| Forward Price To Earnings Growth Ratio | 0.011 | ▲0.057 | ▼-0.008 |
| Price To Earnings Diluted Ratio | -0.802 | ▼-0.409 | ▲1.163 |
| Price To Earnings Diluted Growth Ratio | 0.011 | ▲0.057 | ▼-0.008 |
| Price To Book Ratio | 0.608 | ▲1.843 | ▼-0.968 |
| Price To Sales Ratio | 11.389 | ▲11.389 | ▼-3417.878 |
| Price To Free Cash Flow Ratio | -0.855 | ▼-0.241 | ▲1.237 |
| Price To Operating Cash Flow Ratio | -1.727 | ▼-1.112 | ▲0.542 |
| Debt To Assets Ratio | 0.007 | ▼-1.046 | ▼-0.216 |
| Debt To Equity Ratio | 0.008 | ▲2.430 | ▲0.478 |
| Debt To Capital Ratio | 0.008 | ▼-1.696 | ▼-0.347 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-1.704 | ▼-0.341 |
| Financial Leverage Ratio | 1.184 | ▲3.485 | ▲0.699 |
| Working Capital Turnover Ratio | 0.096 | ▲0.096 | ▲0.074 |
| Operating Cash Flow Ratio | -1.983 | ▲1.252 | ▲2.100 |
| Operating Cash Flow Sales Ratio | -6.596 | ▼-6.596 | ▲826.121 |
| Free Cash Flow Operating Cash Flow Ratio | 2.019 | ▲1.019 | ▲0.815 |
| Debt Service Coverage Ratio | -69.416 | ▼-17.568 | ▼-45.163 |
| Interest Coverage Ratio | -69.855 | ▼-11.289 | ▼-44.170 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -43.511 | ▼-42.681 | ▼-9.910 |
| Capital Expenditure Coverage Ratio | -0.981 | ▲3117.559 | ▲1828.808 |
| Dividend Paid And Capex Coverage Ratio | -0.981 | ▲3117.559 | ▲1392.956 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▲0.404 |
| Enterprise Value Multiple | 0.588 | ▲1.082 | ▲1.555 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $123.5M | $19.1M | $149.5M | $159.2M | $74.1M | |
| Enterprise value | -$88.0M | $21.8M | $108.5M | $112.2M | -$14.2M | |
| EV / Sales | -8.12x | 0.00x | 10850.36x | 1496.23x | -12.28x | |
| EV / Op. cash flow | 1.23x | -0.70x | -3.11x | -2.42x | 0.25x | |
| EV / Free cash flow | 0.61x | -0.70x | -3.11x | -2.41x | 0.25x | |
| EV / EBITDA | 0.59x | -0.49x | -2.77x | -2.38x | 0.23x | |
| Net debt / EBITDA | 1.41x | -0.06x | 1.05x | 0.99x | 1.40x | |
| Current ratio | 6.56x | 3.62x | 6.41x | 5.71x | 7.68x | |
| Income quality | 0.47x | 0.82x | 0.94x | 0.99x | 0.91x | |
| Graham net-net | $18 | -$21 | $55 | $74 | $151 | |
| Tax burden | 101.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 101.5% | 109.8% | 94.0% | 98.5% | 100.0% | |
| Working capital | $200.6M | $25.2M | $37.0M | $41.8M | $79.0M | |
| Invested capital | $202.9M | $25.2M | $37.7M | $42.6M | $80.9M | |
| Return on assets | -64.1% | -136.2% | -81.4% | -90.1% | -67.2% | |
| Operating ROA | -110.6% | -123.3% | -80.9% | -64.9% | -53.5% | |
| Return on tangible assets | -64.1% | -136.2% | -81.4% | -90.1% | -67.2% | |
| Return on equity | -75.8% | 313.5% | -96.1% | -108.8% | -77.7% | |
| Return on invested capital | -74.6% | -191.9% | -100.1% | -108.1% | -76.0% | |
| Return on capital employed | -74.7% | -191.9% | -102.1% | -110.4% | -76.9% | |
| Earnings yield | -124.6% | -253.9% | -24.7% | -29.3% | -85.6% | |
| Free cash flow yield | -117.0% | -162.8% | -23.3% | -29.2% | -77.6% | |
| Capex / Op. cash flow | -101.9% | -0.0% | -0.1% | -0.2% | -0.0% | |
| Capex / Depreciation | 86808.3% | 28.4% | 14.0% | 40.6% | 5.6% | |
| Capex / Sales | 672.4% | 0.0% | 213.9% | 112.3% | 1.3% | |
| SG&A / Sales | 234.1% | 0.0% | 192130.0% | 25449.3% | 1475.8% | |
| R&D / Sales | 1273.4% | 0.0% | 200716.6% | 37854.5% | 4094.9% | |
| Stock comp / Sales | 122.6% | 0.0% | 35604.8% | 5143.4% | 524.9% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 606d | 0d | 6417d | 701d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 606d | 0d | 6417d | 701d | 0d | |
| Cash conversion cycle | 606d | 0d | 6417d | 701d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+546.2%EV / Sales n/aEV / EBITDA ▲+219.0%EV / Op. cash flow ▲+1.933Earnings yield ▲+1.292
Profitability
Return on equity ▼-3.893Return on assets ▲+0.722Return on invested capital ▲+1.173Return on capital employed ▲+1.172Operating ROA ▲+0.127Income quality ▼-0.356Tax burden ▲+0.013
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+2.940Net debt / EBITDA ▲+1.475Working capital ▲+175393000.000Invested capital ▲+177708000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+66.7%EV / Sales ▲+33.9%EV / EBITDA ▲+161.0%EV / Op. cash flow ▲+0.983Earnings yield ▼-0.390
Profitability
Return on equity ▲+0.019Return on assets ▲+0.032Return on invested capital ▲+0.014Return on capital employed ▲+0.021Operating ROA ▼-0.571Income quality ▼-0.442Tax burden ▲+0.013
Efficiency
Days sales outstanding ▲+605.441Days payables outstanding n/aOperating cycle ▲+605.441Cash conversion cycle ▲+605.441Capex / Sales ▲+6.711R&D / Sales ▼-28.215
Balance-sheet strength
Current ratio ▼-1.117Net debt / EBITDA ▲+0.015Working capital ▲+121618696.000Invested capital ▲+121988669.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-21 Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,098.00 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Barbara Bispham sold 620 shares of Crescent Biopharma stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total transaction of $11,098.00. Following the transaction, the insider owned 18,710 shares of the company''s stock, valued at
- 2026-09-21 Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $28,819.00 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CEO Joshua Brumm sold 1,610 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total value of $28,819.00. Following the sale, the chief executive officer owned 279,602 shares in the company,
- 2026-09-21 Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,151.70 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Ellie Im sold 623 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total value of $11,151.70. Following the completion of the sale, the insider directly owned 21,446 shares in the company,
- 2026-09-21 Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CFO Sells $10,167.20 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CFO Richard Scalzo sold 568 shares of Crescent Biopharma stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total value of $10,167.20. Following the completion of the transaction, the chief financial officer owned 19,730 shares of
- 2026-09-21 Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,778.20 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) insider Jan Pinkas sold 658 shares of the company''s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total transaction of $11,778.20. Following the transaction, the insider owned 21,581 shares in the company, valued at $386,299.90.
- 2026-09-21 Insider Selling: Crescent Biopharma (NASDAQ:CBIO) COO Sells $13,084.90 in Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) COO Jonathan McNeill sold 731 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total value of $13,084.90. Following the completion of the transaction, the chief operating officer owned 138,427 shares of the
- 2026-09-20 Jonathan Mcneill Sells 3,839 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) COO Jonathan McNeill sold 3,839 shares of the business''s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.71, for a total transaction of $64,149.69. Following the transaction, the chief operating officer directly owned 134,588 shares of the company''s
- 2026-09-20 Joshua Brumm Sells 7,837 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) CEO Joshua Brumm sold 7,837 shares of the business''s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.71, for a total value of $130,956.27. Following the sale, the chief executive officer owned 271,765 shares of the company''s stock,
- 2026-09-17 Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR) Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares Vir
- 2026-09-15 Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript